The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Investors were spooked by slowing sales growth for EYLEA and lack of revenue ... because the median P/E for the company over the past 5 years is at 18, and now the company is valued at 25-27 ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

According to the report, the Abu Dhabi market is well-positioned for growth, driven by new developers entering the market and ...

Ola Electric has confirmed the launch of an electric three-wheeler in the first or second quarter of the upcoming financial ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Updated figures provided through the department’s Urban Development Program (UDP) show completions are down 18 per cent on the five-year average. Loading Developer lobby group Urban Taskforce ...

When I was young man, I met a girl in Tennessee who turned out to be a moonshiner’s daughter. That was a long time ago. But I ...

That denial was partially due to the pipeline route’s conflicts with local county siting laws. “Our focus continues to be on working with landowners and ensuring the long-term viability of ...

Got $5,000? These 5 High-Yield Dividend Stocks Could Turn It Into More Than $300 of Annual Passive Income.